HER2-positive breast cancer and dual-target therapy study
Part of Cancer, Skin clinical trials.
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with primary breast cancer that is stage I, II, or III (has not spread to distant organs).
- Your cancer is HER2-positive, confirmed by a special test (FISH) showing a high HER2/CEP17 ratio.
- You have received at least one dose of trastuzumab and pertuzumab together, either before or after surgery.
- You had surgery to remove your breast cancer (either mastectomy or breast-conserving surgery).
- You have not had previous anti-HER2 treatment before starting this dual-target therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This study tests a new combination of two HER2-targeted drugs (trastuzumab and pertuzumab) given after surgery for HER2-positive breast cancer. It looks at whether this combination can help reduce the risk of cancer coming back in people who still had some cancer left after neoadjuvant therapy.
This trial tests a combination of targeted therapies and hormone therapy for early-stage breast cancer that is HER2-positive and hormone receptor-positive. The goal is to see if this treatment can help shrink the tumor before surgery.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.